Master's thesis

Jon Bro Flak

Sequencing and Electrophysiological Characterization of the Repolarizing KCNQ1 Channel Found in the Equine Heart



Academic advisors:

Professor M.D. Dan Arne Klærke & Ph-D student, DVM Philip J. Pedersen

Submitted: 05/08/13

Institute:	Institute for Clinical Veterinary and Animal Science
Name of department:	Department of Physiology
Author):	Jon Bro Flak

Title and possible Subtitle: Sequencing and Electrophysiological Characterization of the Repolarizing KCNQ1 Channel Found in the Equine Heart

Front page illustration: a graphic model of a DNA double helix highlighting a mutation site adapted from (IO9 2013)

Preface

This project is my master's thesis done as part of the master in veterinary medicine at the University of Copenhagen. The project is also done in close collaboration with the Ph-D project of Philip J. Pedersen. In the broader perspective the goal of the project is to help identify reasons for cardiac death in horses and to gain better understanding of the ion channels and their function in the equine heart. This will be done by mapping the I_{kr} and I_{ks} channels including their sub units, and expressing them in *Xenopus* oocytes to measure their function and responses to certain potentially pro-arrhythmic drugs.

In this particular study the KCNQ1 and KCNE1 and 2 are in focus as they were the ones that the most information could be ascertained about through PCR.

I would like to give thanks to the laboratory technicians of the department, and special thanks to my supervisors Dan A. Klærke, and Philip J. Pedersen who were always willing to help and give advice and along with all members of the department create a good work atmosphere.

And to my pregnant wife and my daughter: All my love for enduring my frequent absence during this project.

Abstract

Sudden death (SD) in horses is a great problem in equine athletics. In up to 22% of SD there is never found an underlying pathological cause, raising the question if there is a molecular basis to these cases of SD. In this study PCR was utilized to find parts of the equine sequences of KCNQ1, and KCNE1. The entire equine CDS of KCNQ1, KCNH2, KCNE1 and KCNE2 (with a few assumptions) was then individually analyzed by comparison to their human counterparts via BLAST, both nucleotide and protein sequences. It was especially investigated if there were any registered human LQTS mutations present in the equine sequences. KCNQ1 contained 3 protein dissimilarities identical to human mutations and a few more at same sites. KCNE1 also had human mutations present. KCNH2 had only one protein dissimilarity 1bp adjacent to a registered human mutation linked to LQT2. KCNE2 had only 3 such adjacencies. The conclusion to this is that the equine I_{Ks} current might be different from the human, whereas the I_{Kr} might be a good human homologue. The mutation analysis also gives good reason to believe there might be an equine form of LQTS, and emphasizes the need for drug studies for equine specific drugs.

KCNQ1, KCNE1 and KCNE2 were synthesized from the data we had, and attempted sub cloned in to a p-Xoom vector. This was however not achieved within the duration of this project. Therefor expression in *Xenopus* oocytes was not achieved either.

Table of Contents

Preface	2
Abstract	2
Theoretical Background	4
Sudden Death in Horses	4
The Cardiac Action Potential	4
Channel Structure and Composition	5
Long QT Syndrome	6
Methods	8
Bioinformatics	8
PCR	8
Sequencing	10
Ligation, Transformation and Cloning:	10
Plasmid Purification:	11
Gene Synthesis and Sub Cloning	11
Results	13
PCR and Sequencing	13
Subcloning	13
Gene Analysis	14
Conclusion	16
Discussion	17
References	19
Appendices	21
Apendix I Primers used	21
Apendix II KCNQ1	22
Apendix III KCNH2	26
Apendix IV KCNE1	32
Apendix V KCNE2	33

Theoretical Background

Sudden Death in Horses

Sudden Death (SD) is a well-known problem in equine athletics. A retrospective study has been made to identify the causes of sudden death during or soon after exercise. A great proportion, up to 22% had no apparent cause despite a thorough post mortem pathological examination. (Lyle, Turley et al. 2010, Lyle, Uzal et al. 2011)

One study found histopathological similarities in 5 SD horses. 3 lesions were apparent in all 5 cases: Atrial myocardial fibrosis near the SA node, sclerotic vascular changes of the AV and SA node arteries, and fibroplastic and/or fibrotic lesions in the upper portion of the interventricular septum. These lesions were comparable with the fact that they showed cardiac symptoms at death. One horse even had perimortal ECG readings showing supra ventricular premature complexes and ventricular premature complexes up until ventricular fibrilation and subsequent death. However the mechanism for these changes, and the other unexplained equine exercise related deaths demand further research. (Kiryu, Machida et al. 1999)

A reason for the missing cause of death in many cases of SD in horses is not only due to the fact that no pathological anomalies are found, in most cases it is due to no post mortem examination at all. The data processed in the articles is mainly derived from racing associations' databases, and not all racing jurisdictions require mandatory post mortem examinations. This does however not invalidate the data given in this study in any way. Furthermore in cases where post mortem examination is performed the necropsy will only detect macroscopic changes, and perform histology when indicated or suspected. In the cases of arrhythmogenic heart failure there may not be any macro- or histo-pathological anomalies, so to do molecular testing, to dig deeper, it is necessary to understand the underlying electrophysiological mechanisms of the equine action potential.

The Cardiac Action Potential

The heart functions by sequentially triggering different ion channels through a single heartbeat; this



Figure 1: An overview of the channels involved at the different phases in the cardiac action potential. Adapted from Wikimedia commons

sequence is known as the action potential. The action potential can be divided into 5 phases (0-4) depending on what channels are active (fig1). Phase 0 is characterized by the rapid influx of sodium which depolarizes the cell membrane from approximately -90 to > +20mV. Phase 1 is a quick partial repolarization, a result of outward flow of potassium. Phase 2 also known as the plateau phase is an equilibrium between several channels, notably inward calcium, outward potassium and calcium sodium exchange channels. Phase 3 initiates as the inward calcium flow ends leaving the outward potassium flow dominate returning the cell to its resting potential of -90mV, thus starting Phase 4 where inward rectifier potassium channels keep the myocyte at its resting potential. (Nerbonne and Kass 2005)

Each channel in the heart cell membrane serves a specific purpose in the action potential. The I_{Ks} and I_{Kr} channels are responsible for the transport of potassium ions out of the cell in the phases 2-3, and their main constituents are KCNQ1 and KCNH2 respectively. (Nerbonne and Kass 2005)

Channel Structure and Composition

Most Potassium channels consist of 4 identical protein sub units comprising a homotetramer, and generally exist in 2 types based on the number of trans-membrane helices each subunit contains. The channels KscA(*Streptomyces Lividans*) which has 2 trans-membrane helices, and Shaker(*Drosophila Melanogaster*), 6 helices, lay the foundation for most of the knowledge there is about potassium channels. Shaker is the one most often compared to, since mammalian potassium channels have 6 trans-membrane helices. (Doyle, Morais et al. 1998) In addition, certain K channels, the socalled two-pore-channels consist of two subunits with each 4 transmembrane segments.

Potassium channels have what is known as a signature sequence of 8 amino acids (TXXTXGYG), where X is a random amino acid. This is also the selectivity filter which is responsible for the channels' extremely high affinity for potassium ions. In one study mutagenesis was used to examine how changes in the signature sequence would affect the channels kinetics. Some amino acid substitutions were tolerated without changing the affinity remarkably, while others ruined the function of the channel. (Heginbotham, Lu et al. 1994)

KCNQ1 and KCNE1

KCNQ1, formerly known as KvLQT1, was originally found and named due to its implication in the hereditary disease complex of Long QT Syndrome (LQTS). LTQS was at the time known to come in chromosome linked variants. KCNQ1 was thus found as the Chromosome-11 associated LQTS gene through positional cloning. KCNQ1 is classified as a voltage dependent delayed rectifier and is active during phase 2-3. (Wang, Curran et al. 1996)

KCNQ1 only forms the α sub unit of I_{Ks}. For it to yield the same current and function it needs to be coexpressed with the β sub unit made up from the gene KCNE1. Together they form the functional KCNQ1 channel, which is partly responsible for repolarization of the cardiac action potential (Sanguinetti, Curran et al. 1996)

A study has shown that the co-expression of these two sub units, at least in *Xenopus Laevus* oocytes, is transitory in the sense that KCNE1 presence in the cell membrane dwindles over time. The study described it as a "kiss and go" effect that 10 days in to the experiment left the $\alpha+\beta$ oocytes' electrical currents indistinguishable from the α oocytes' suggesting that the β sub unit is synthesized and transported to the outer cell membrane separately and may be involved in regulation of the KCNQ1 function. (Poulsen and Klaerke 2007)



Figure 2: A simplified schematic of the α sub units of I_{Kr} and I_{Ks} left to right. The colored dots mark mutation sites related to LQT2 and LQT1 respectively as adapted from (Nerbonne and Kass 2005)

KCNH2 and KCNE2

KCNH2 is the main component of the I_{Kr} current and is also known as the Ether-a-go-go Related Gene or ERG, in humans this becomes hERG. (Warmke and Ganetzky 1994) KCNH2 is, like KCNQ1, a voltage dependent delayed rectifier, but mostly active in Phase 3. The reason for the later activation is that KCNH2 has a dual gating mechanism, which consists of an activation gate and an inactivation gate positioned on the intra- and extracellular sides of the membrane respectively. Both gates must be open for potassium current to flow. The gates react to the same changes in membrane potential but in different ways. The activation gate opens on depolarization and closes on repolarization, and vice versa for the inactivation gate. However the inactivation gate responds faster to the change in membrane potential opening it a fraction of time before the activation gate can close. This potentiates the already ongoing repolarization during phase 3 of the action potential. (Witchel, Milnes et al. 2002) The β sub unit KCNE2 is thought to be coexpressed with the ERG channel in order to regulate the I_{Ks} current. (Nerbonne and Kass 2005)

KCNH2 was until its discovery known as Chromosome-7 linked LQTS gene and is like KCNQ1 partly responsible for the repolarization of the cardiac action potential.

Long QT Syndrome

LQTS is a condition that puts a patient at significant risk of syncope and/or sudden death. It is diagnosed weighted on multiple criteria of which a long QT interval is one. The diagnosis is also based on patient and/or family history of syncope or sudden death. Another ECG finding relevant for the diagnosis of LTQS is Torsades de Pointes arrhythmias. LQTS comes both as an acquired form and a congenital. The acquired form is usually due to illicit or prescribed drug use, ischemic injury or other mechanical malformations in



the heart. The congenital form is related to 12 different genes (LQT1 -12). Of these genes KCNH2 and KCNQ1 are the most important. (Hedley, Jorgensen et al. 2009)

Figure 3: An ECG showing Torsades de Pointes adapted from (Tan, Hou et al. 1995)

In humans, one study claims that KCNQ1 accounts for more than 50% of the congenital cases of LQTS, LQT1. (Wang, Curran et al. 1996) KCNH2 is also related to a congenital form; LQT2, but is more known for its high sensitivity to a variety of drugs inducing an acquired LQT2.(Sanguinetti, Jiang et al. 1995) KCNH2 may account for up to 45% of congenital LTQS cases.(Splawski, Shen et al. 2000) The main focus of this project will be on these 2 genes as they are some of the major contributors to LQTS in the human population.

KCNE1 and KCNE2 are linked to the hereditary forms of LQTS: LQT5 and LQT6 respectively(Hedley, Jorgensen et al. 2009)

Both KCNQ1 and KCNH2 and their sub units of the KCNE family have been found in equine heart tissue via immunoblotting and RT-PCR. The same study measured electrophysiological currents similar to those of human homologues, suggesting that the repolarization mechanisms of the equine heart are also susceptible to LQTS. (Finley, Li et al. 2002)



Figure 4: A graphic presentation showing the ECG and the action potential along the same time axis. Adapted from(Tan, Hou et al. 1995)

Methods

Bioinformatics

NCBI'S Basic Local Alignment Tool (BLAST) was used for all nucleotide and peptide searches pertaining to sequencing results, inter species comparison and primer design. <u>http://blast.ncbi.nlm.nih.gov_All BLAST's</u> will have equine sequence as query and human sequence as subject.

The NCBI database ClinVar: <u>http://www.ncbi.nlm.nih.gov/clinvar</u> and the web site: <u>http://www.fsm.it/cardmoc/</u> were used for looking up registered human missense mutations related to KCNQ1, which were then compared to the equine sequence we had obtained. Frame shift and silent mutations were considered irrelevant to this study.

The TMHMM 2.0 tool: <u>http://www.cbs.dtu.dk/services/TMHMM/</u> was used for predicting membrane topology of the found equine sequences so it could be compared to what is known about their human homologues.

Primers were designed using OligoCalc at: <u>http://www.basic.northwestern.edu/biotools/oligocalc.html</u> with the only modification from pre fixed settings that the concentration of primer is 500 nM instead of the 50 nM. The primers 67 and 68 (appendix I) were designed by me during this project and were designed to have an annealing temperature around 60°C, not be much longer than 20bp, as low GC% as possible, no more than 3 (2 is better) repeating C's or G's e.g. CCC or GGG and to end in a single G or C. All primers were tested for hairpin and auto-dimerization formation and judged usable if the pre fixed settings gave no matches for self-complementarity.

PCR

As this project was a continuation of work previously done by master student (Olander 2012), some information about the equine sequence of KCNQ1, KCNH2 and KCNE 1-4 was already available. It will be specified in the results section and relevant appendices of this project what data was found before and what was found during this project. The focus of this project was however, due to this, focused on finding the 5' CDS and UTR ends of the genes.



5' RACE PCR was therefore utilized to investigate these regions. The FirstChoice[®] RLM-RACE kit from Ambion[®] was used. This kit works by in vitro treating RNA harvested from equine myocardium just after euthanasia, removing the phosphorous cap at the 5' terminal of m-RNA and substituting it with a synthesized RNA adapter. This can then be reverse trans-scripted into cDNA, to which ready to use application oligonucleotide primers are included in the kit that fit the now present adapter. This means that it should only be mRNA with a complete 5' end that will be amplified using PCR, and that a reverse gene specific primer (GSP) is all that is needed since the forward primers are a known part of the adapter.

Figure 5: A schematic representation of the RLM-cDNA synthesis procedure. Adapted from the FirstChoice[®] kit. Calf Intestinal Phosphatase (CIP), Tobacco Acid Pyrophasphatase (TAP). This was set up as a nested PCR meaning that first a PCR was set up with the 5' RACE outer primer of the kit and a GSP, using the adapted RNA as template. Then a second PCR was set up using the 5' RACE inner primer and another GSP slightly upstream from the first GSP, using the first PCR as template thus creating higher specificity for the wanted product. Due to empirical experience an additional technique was implemented to further specify the PCR. This was Touch Down (TD) PCR, in which the first 5 cycles the annealing temperature is set at 4°C above the expected and taken down 1°C each cycle through the first 5. The remaining cycles are the run at the expected annealing temperature (table 2).

The Phire Hot start II DNA Polymerase Kit (FS-122) from Thermo scientific was used for most of the PCR reactions. One reaction, the KCNQ1 results, was done with the FS-120 kit containing Phire I. All of the reactions were run on a Piko[®] Thermal cycler from Finnzymes[®]. The general composition of PCR solution is shown here in Table 1

Reaction Component	Ammount for a single 10µl reaction
dH2O	5,6 μΙ
5X Reaction buffer containing loading dye	2 μΙ
dNTP Mix	0,2 μΙ
Forward primer	0,5 μΙ
Reverse primer	0,5 μΙ
Template	1 μΙ
Polymerase enzyme	0,2 μΙ

Table 1: The general composition of a PCR solution. Used to prepare master mixes where primers and template were added individually to the reaction tubes.

Due to the empirical experience of my Councilor the standard PCR protocol was augmented, as previously mentioned, using the following adjustments the ones written in red being different from product manual guidelines:

Step	Temperature	Time	Notes
Initial denaturation	98°C	45s	
Denaturation	98°C	6s	
Annealing	Primer specific +4°C	6s	Repeat 4 times, dropping extension temp. 1°C each time
Extension	72°C	Dependent on expected length	
Denaturation	98°C	6s	
Annealing	Primer specific	6s	Repeat 20 and 25 times for outer and inner reaction respectively
Extension	72°C	Dependent on expected length	
Final extension	72°C	1min	Cooled to 4° immediately after this step

Table 2: a schematic view of the Nested TD PCR protocol utilized in this project, adapted from the technical manual of the FS-122 kit.

All gels were made with TBE buffer and 2% agarose since we were expecting shorter segments (<1000bp). The Gels were mixed with Ethidium Bromide for later UV Trans-lumination on a UVP MultiDoc It Digital Imaging Systems from AH Diagnostics. Gels were run at 60V corresponding to 4V per centimeter between the electrodes of the electrophoresis tub. The Phire[®] II kit had loading capabilities in the reaction buffer, but the reactions done with Phire[®] I were mixed with loading buffer on parafilm first. Each well was loaded with 1 μ l of PCR reaction alongside a 100bp ladder from NEB[®]

Sequencing

Sequencing was done by Eurofinns MWG Operon sequencing department in Germany, the KCNQ1 results of this project was done on a cloned Vector insert. KCNE1 results were sent as unpurified PCR solutions having only been evaluated on a gel. This allowed for much faster responses and proved to be reliable enough that we went forward with the method.

Ligation, Transformation and Cloning:

Cloning was performed using the TOPO[®] TA cloning[®] kit from Invitrogen[™]. Prior to the ligation the PCR solution was incubated at 72°C for 10-15 minutes with the Taq-polymerase. This adds dA overhangs on the 3' strands of the PCR product which was left with blunt ends after the Phire-polymerase reaction. Thus enabling it to fit with the dT overhangs of the pCR[™] 4-TOPO[®] vector. The *E. Coli* strain used was the One-Shot[®] TOP10. All liquid mediums and the agar plates were mixed with 100µg/ml ampicillin for vector selectivity.

The transformation was done by mixing PCR product and the vector. This mixture was then added to a vial of *E. Coli* and left to incubate on ice for about 30 minutes. The culture was then heat shocked at 42°C for

exactly 30 seconds and then immediately put on ice again. Soon after S.O.C. medium was added to the vial and it was left to incubate at 37°C semi horizontally at 200 RPM for an hour. Here after the suspension was plated on to LB agar plates and left over night at 37°C. The following day the colonies were singled out and transferred to another liquid LB suspension to be cultured for 16 hours. A glycerol stock was made of this to be stored at -80°.

Plasmid Purification:

Plasmid purification was performed with the GeneElute™ plasmid miniprep kit from Sigma-Aldrich. The

Bacterial culture

Experienced User Protocol All spins at \geq 12,000 \times g, except as noted. 1 Harvest & lyse bacteria Pellet cells from 1–5 ml overnight culture 1 minute (1 ml from TB or 2xYT; 1-5 ml from LB medium). Discard supernatant. Resuspend cells in 200 µl Resuspension Solution. Pipette up and down or vortex. Add 200 µl of Lysis Solution. Invertigently to mix. Do not vortex. Allow to clear for ≤5 minutes Prior to first time use, be sure to add the RNase A to the Resuspension Solution. 2 Prepare cleared lysate Add 350 µl of Neutralization Solution (S3). Invert 4-6 times to mix. Pellet debris 10 minutes at max speed. 3 Prepare binding column Add 500 ml Column Preparation Solution to binding column in a collection tube □ Spin at \geq 12,000 × q, 1 minute. Discard flow-through 4 Bind plasmid DNA to column Transfer cleared lysate into binding column. Spin 30,1 minute. Discard flow-through. 5 Wash to remove contaminants D Optional (EndA+ strains only): Add 500 µl Optional Wash Solution to column. Spin 30, 1 minute. Discard flow-through. Add 750 µl Wash Solution to column. Spin 30", 1 minute. Discard flowthrough. Spin 1 minute to dry column. Prior to first time use, be sure to add ethanol to the concentrated Wash Solution 6 Elute purified plasmid DNA Transfer column to new collection tube. Add 100 µl Elution Solution. Spin 1 minute. If a more concentrated plasmid DNA prep is required, reduce the elution volume to a minimum of 50 µl. Figure 6: A simple overview of the plasmid purification as adapted from the GenElute[™] Plasmid Miniprep kit

Pure Plasmid DNA

procedure was done in accordance with the user guide, with the included recommendations for lastly eluting with 5mM Tris-HCl and reduced volume to optimize for sequencing use as seen in step 6 of figure 6.

The purified eluent was messuredonaNanoDrop™3300SpectrophotometerfromThermoScientific

Gene Synthesis and Sub Cloning

KCNQ1 (2050bp), The KCNE1 (409bp) and -2 (391bp) Genes, as derived from the results, were ordered from www.Genescript.com on the 17-06-13 and were produced via their protocols, we ordered it to be provided in their pUC57-kan vector inserted at EcoR(I). For all 3 genes we added BStE(II) immediately downstream of the CDS so we could insert the sequence with directionality into the p-Xoom vector (5052bp). It was checked that none of the genes contained these restriction sites.

The restriction enzymes EcoRI and BstEII, both High Fidelity (HF) versions, were ordered from New England Biolabs[®] (NEB) and were used with CutSmart[™] buffer (NEB).

The Genes were cut out using a double digest and the p-Xoom vector was linearized in the same way. The reaction was set up with 1µg DNA derived from measurements on the Nanodrop machine, 1µl of each enzyme (20.000u/ml), 3µl Cutsmart[™] buffer, 3µl 10X Bovine Serum Albumine and dH2O added to a total of 30µl. These reactions were incubated at 37°C for 4 hours, then 5µl of 6X loading dye were added. The total

solution was loaded on a gel and run at about 100V. The KCNE genes were loaded on 2% agarose and the KCNQ1 and linearized vector were loaded on 1% agarose. The gels were then transluminated to evaluate the digestion and to visualize the bands in order to cut them out. This was done with a rectangular pipette transferring the gel piece to an 1,5ml eppendorf tube.

The DNA was extracted from the gel using the QIAquick[®] Gel Extraction Kit adapting some of the therein mentioned optimizations. These were leaving the PE-buffer atop the filter for 2 minutes prior to spinning the column to optimize for later salt sensitive reactions in the ligation. Also the final elution was done with 30µl 10mM Tris-HCL instead of 50µl to increase the DNA concentration.

The three ligation reactions were performed optimizing the molar ratio of insert to plasmid 3:1 not exceeding 100ng DNA, then adding 1µl T4 ligase enzyme, 2µl 10X T4 reaction buffer and adding dH2O to a total of 20µl per reaction. The mixture was left to incubate at room temperature for 2 hours and hereafter transferred to ice.

The Transformation was done using DH10B chemically competent *E. Coli.* 1µl of the ligation reaction was added to 100µl of DH10B culture thawed on ice from a -80°C stock, then left to incubate on ice for 30 minutes. Next step was heat shocking for exactly 45 seconds at 42°C on a heat block and then immediately transferring the tubes to ice again. Then 0,9ml of S.O.C. medium was added and the culture was left to incubate at 37°C and 225 Rpm vertically. The cultures were then spread on LB plates infused with 100µg/ml neomycin which the p-Xoom vector confers resistance to. Each culture had a plate with 50µl and 125µl spread onto it. These plates were left at 37°C overnight. Alongside, a negative control of the cut p-Xoom was attempted transformed as to have a background template for evaluating the plates the following day. This way we could evaluate if the vector had some self-ligating properties even though a double digest without compatible ends made it unlikely.

The plates which had growth had colonies selected from them which were resuspended in 1X PCR solution, without primers or enzymes, and spread on a grid plate. This PCR slur was then heat treated at 70°C for 5 minutes to destroy the cells and make the DNA accessible. It was then used as template for PCR to confirm the inserts were in the clones. For each reaction the same forward primer (IVTF appendix I) lying upstream of the insert was used with a gene specific reverse primer. All the reactions were done at the same time and run at 58°C since the gene specific primers used had all given results at this temperature. The extension time was set to 500bp or 5 seconds as the longest expected fragment would be around 390bp. These gels were also evaluated via translumination. The grid plate was checked the day after.

This is how far this project got before we would have moved on to in vitro transcription of the DNA into mRNA and used this to inject into *Xenopus* oocytes, to measure the currents via two-clamp electrode testing.

Results

PCR and Sequencing



Figure 7: The first gel shows a product from KCNQ1 using primer 63 and 62 (appendix I) with the Ambion 5' outer and inner respectively, in a nested TD reaction with a length of ca. 120 bp; The second gel shows a product from KCNE1 using primer 68 and 67 (appendix I) with the Ambion 5' outer and inner respectively, in a nested TD reaction with a length of ca. 190 bp; Note: The middle ladder of the second gel was loaded erroneously so it is to be disregarded.

A roughly 120bp segment of KCNQ1 was amplified using primers 62 and 63 (appendix I) along with the Ambion 5' primers. The left over reaction was then given dA overhangs with the Taq-polymerase, ligated with the TOPO TA Vector and then transformed into DHB TOP10 chemically competent *E. Coli* cells. From these the plasmids were extracted in a mini-prep kit and shipped for sequencing yielding the following result not Showing vector:

5'-GCACTTCCAGCCCGTGGGGGCGCTCGAGGAAGTT**GTA**GACGCGGCCTCCTCCCCGCCC<u>AGGGCCGAGAGGAAGCG</u> <u>CTG</u>-3'

The bold is where we assume the start sequence is and the underlined is the part of the equine sequence that was already known to us.

A roughly 190bp segment of KCNE1 was amplified using primers 68 and 67 (appendix I) along with the Ambion 5' primers. The left over reaction associated with the bands (figure 7) was pooled for a 17µl sample which was sent directly to sequencing yielding the following result:

5'-GTGCCCTGCGCTCGGCCAGCGCGGACCTCGCTGCACTGCTGCTCTCTCGGCGCCCCAAACCCGGACATTCCCTCTCC AGCAGTGTAACCTTGAAGCCCAGG**ATG**ATCCTGTCTAACACCACAGCTGTGATGCCCTTTCTGGCCAAGCTGT-3'

In the UTR of both results there were no in frame stop codons to definitely confirm the actual start codon. There were nor any start codons to suggest the contrary though. So we assume the start codons are the ones we have chosen.

During this project only PCR of KCNQ1 and KCNE1 yielded any new data. Attempts were made at amplifying 5' ends of KCNH2 and KCNE 2-4 as well however without luck. It was also attempted to amplify KCNQ1 as one continuous piece, also without luck.

Subcloning

The excision double digestion of the 3 genes gave 2 distinct bands of the expected lengths each (pUC-57 vector and insert). While the double digest to linearize the p-Xoom vector only showed the approximately 5kb band, even though it was attempted to visualize the 40bp excision between EcoRI and BSTEII to confirm the digestion.



Figure 8: a graphic representation of the first steps of the subcloning process up until transformation. Adapted from (Addgene 2013)

During transformation the negative control or background plate with linearized p-Xoom did not have any growth over a 2 day period, this was done to see if the linearized vector had self-ligating properties. However the KCNE1 and -2 plates each had only 1 visible colony overnight and none further after another day. The uncut p-Xoom and KCNQ1 plates showed an abundance of colonies. 4 distinct KCNQ1, 2 p-Xoom and both KCNE colonies were selected for PCR testing and spread on a grid plate. The grid plate had growth in all but the 4 KCNQ1 grids.

The inserts of the final vector were quality tested via PCR with gene specific primers. This however yielded no visible bands aside from the ladder. When they should have showed single bands between 300 and 400bp

Gene Analysis

KCNQ1

A nucleotide comparison of our equine sequence against the human KCNQ1 CDS (NM_000218.2) shows 90% identities, and 100% overlap. There are 12 gaps, 6 in each species. The first 24 bp of the sequence is the part that has been deduced during this project (Blue appendix II). Due to the time constraints of this project, we have assumed that the ATG start sequence is actually there, since the sequencing results we received had the first 3 bp as GTA, making GTA \rightarrow ATG (see 1. sequencing result page13). In the sequencing result it was however also noted that the G and A were not highly probable (Turquoise appendix II). This was necessary in order to move on to oocyte expression so that we would have a complete CDS.

A protein comparison shows 91-93% similarity, the latter being % positives. 3 amino acid dissimilarities are identical to human mutations linked to LQT1 or cardiac arrhythmia (Red appendix II). Another 6 dissimilarities are directly at sites of human mutations but were not identical to the ones registered, and

finally 8 other dissimilarities are 1 amino acid adjacent of a registered human mutation (Yellow appendix II). 1 of the 6; and 1 of the 8 dissimilarities are inside a trans-membrane helix S2 and S1 respectively.

KCNH2

A nucleotide comparison of our equine sequence against the human KCNH2 CDS (NM_000238.3) shows 93% identities, and 100% overlap. There are 3 gaps, corresponding to a 3bp in frame deletion at 881bp of the equine sequence.

The protein comparison shows 98% similarity and only 1 dissimilarity is 1bp adjacent to a registered human mutation linked to LQT2 (Yellow appendix III). There are no dissimilarities in any of the trans-membrane helices.

KCNE1

A nucleotide comparison of our equine sequence against the human KCNE1 CDS (NM_000219.4) shows 85% identities, and 100% overlap. There are 2 gaps, one in each species.

The protein comparison shows 80-87% similarity. 1 amino acid dissimilarity is identical to a human mutation linked to LQT5 (Red appendix IV). Another 3 dissimilarities are directly at sites of human mutations but are not identical to the ones registered, and finally 8 other dissimilarities are 1 amino acid adjacent of a registered human mutation (Yellow appendix IV). One of the 3 dissimilarities is the only one inside the trans-membrane helix.

KCNE2

A nucleotide COMPARISON of our equine sequence against the human KCNE2 CDS (NM_172201.1) shows 87% identities, and 100% overlap. There are 0 gaps.

The protein COMPARISON shows 89-95% similarity. There are no dissimilarities directly at human mutation sites. There are 3 dissimilarities which are 1 amino acid adjacent of a registered human mutation (Yellow appendix V). There are no dissimilarities inside the trans-membrane helix.

Conclusion

Equine KCNQ1 and KCNE1 are overall comparable to their human counterparts, however there are many dissimilarities when BLAST'ed and several of these where at registered sites of human mutations linked to LQT1 and LQT6 respectively. Considering this it is likely that congenital LQTS may be found in the equine population. It also suggests that the entire I_{KS} channel may have different kinetics from the human.

Considering KCNH2 there is very little difference from the human protein. And that only one dissimilarity was adjacent to a registered human mutation. The 98% protein similarity is somewhat higher than the other proteins, which is a noteworthy finding in itself. It cannot be contributed to this project however.

KCNE2 has only a few dissimilarities adjacent to registered human mutation sites. Otherwise there is good similarity. This combined with the knowledge of KCNH2 suggests that the I_{Kr} Channel complex is more like its human counterpart at least compared to I_{Ks} .

None of the genes have been definitely confirmed via in frame 5'-UTR stop codons.

Discussion

Animals have been used for models of human LQTS, in particular dogs used for medical trials. This is done by crushing part of the SA node and utilizing β blockade to induce bradycardia. This is of course done under anesthesia. Then the study drugs, in the case of this reference H1-antagonsitic antihistamines, are administered to see if they have detrimental effects on the ECG of the dog.(Weissenburger, Noyer et al. 1999)

These pharmacological conditions are not optimal since it cannot be known for sure whether β -blockade and or anesthesia interact with the test drug to either potentiate or negate any effects. Therefore a genetic approach to understanding the kinetics of the cardiac action potential in animals is important as it may lead to the finding of a spontaneous animal model for LQTS. Furthermore a broader understanding may lead to better in vitro testing capabilities as to reduce the number of test animals needed for research such as this.

One study has found spontaneous examples of acquired LQTS in dogs. (Campbell and Atwell 2002) Where in 39 cases dogs were admitted to the clinic suffering from tick toxicity (*Ixodes Holocyclus*) where they had ECG's done at admission, 24 hours later, at discharge, when clinically well and approximately 12 months later. These results showed that the dogs had prolonged QT intervals (corrected for heart rate) and abnormal T-wave morphology comparable to that of human LQTS. These ECG findings were present after clinical remission, but none had any ECG abnormalities 12 months after admission.

Another study have found congenital forms of LQTS in a canine population, I have however been unable to find the source which was mentioned to me by my advisor despite thorough searches on the OvidSP through our faculty library web page(Library 2013) so this will have to be confirmed.

This indicates that LQTS is a valid problem in animal populations, and we should therefor take care what drugs we use in animals. A study has tried to evaluate a few suspected sedatives with regard to echocardiographic evaluation. It was, among other things, found that romifidine and detomidine gave significantly reduced heart rate.(Buhl, Ersboll et al. 2007) This would be more severe if the horse already has an LQTS diathesis.

This problem of not knowing which drugs are detrimental to the equine heart was also a part of the master's thesis (Olander 2012) where she showed that Acepromazine could block the ERG channel expressed in *Xenopus* oocytes. Given time it would have been the goal of this project as well to try some of these suspected drugs in vitro on KCNQ1 with and without the KCNE1 subunit. Perhaps also try the KCNH2 experiments along with the KCNE2 subunit this time.

Analysis of KCNQ1's genomic structure indicates that it should not be expected to behave completely identical to the human channel. This emphasizes the need to screen drugs on a species level, and not to assume that human approved drugs have the same kinetics in horses. The next steps to express the channels and the subunits are an important step in this direction.

Analysis of KCNH2 on the other hand suggests that it might be a good human homologue. The high similarity might be explained by the channels dual gating mechanism and or its high sensitivity to drugs,

meaning that mutations are badly tolerated leading to high conservation. This is however my own speculation.

Another aspect of identifying the equine sequence is that it enables the possibility to screen the population for mutations and perhaps identify horses at risk of getting cardiac diseases, or post mortem identify possible reasons for sudden death. In the long run to improve the breeding of horses to perhaps eliminate carriers from the breeding programs. This is also a reason for debate as many horse owners may not be willing to start testing their horses out of fear of potentially losing the profitability of a valuable stallion or mare.

With regard to why the PCR quality control of our sub cloned vector failed to produce bands, it was not entirely clear if the forward primer IVT-forward (appendix I) was genuine. It was last used by a former Ph-D student whose data and notes we then had to interpret. Therefor after our failed attempt my last action in the laboratory, before committing to writing, was to order a new stock of the primer as well as a reverse primer downstream of the insert. So another attempt can be made.

Also during the sub cloning process, when no 40bp band was visualized at the linearization of the p-Xoom vector it might be due to such a small fragment easily diffusing through the gel making the concentration too low to see.

More research is needed to definitely confirm the 5' ends of all four genes preferably by locating in frame stop codons in the 5' UTR. Also the actual Start codon of KCNQ1 needs to be verified, as do the 5' and 3' ends of KCNE2. The 5' RACE process seems good enough to do this the process just has to be tweaked some more.

References

Addgene. (2013). Retrieved 08-05, 2013, from <u>http://www.addgene.org/static/cms/images/Restriction-Enzyme-based-Subcloning.gif</u>.

Buhl, R., A. K. Ersboll, N. H. Larsen, L. Eriksen and J. Koch (2007). "The effects of detomidine, romifidine or acepromazine on echocardiographic measurements and cardiac function in normal horses." <u>Vet Anaesth Analg</u> **34**(1): 1-8.

Campbell, F. E. and R. B. Atwell (2002). "Long QT syndrome in dogs with tick toxicity (Ixodes holocyclus)." <u>Aust Vet J</u> **80**(10): 611-616.

Doyle, D. A., C. J. Morais, R. A. Pfuetzner, A. Kuo, J. M. Gulbis, S. L. Cohen, B. T. Chait and R. MacKinnon (1998). "The structure of the potassium channel: molecular basis of K+ conduction and selectivity." <u>Science</u> **280**(5360): 69-77.

Finley, M. R., Y. Li, F. Hua, J. Lillich, K. E. Mitchell, S. Ganta, R. F. Gilmour, Jr. and L. C. Freeman (2002). "Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart." <u>Am.J.Physiol Heart Circ.Physiol</u> **283**(1): H126-H138.

Hedley, P. L., P. Jorgensen, S. Schlamowitz, R. Wangari, J. Moolman-Smook, P. A. Brink, J. K. Kanters, V. A. Corfield and M. Christiansen (2009). "The genetic basis of long QT and short QT syndromes: a mutation update." <u>Hum.Mutat.</u> **30**(11): 1486-1511.

Heginbotham, L., Z. Lu, T. Abramson and R. MacKinnon (1994). "Mutations in the K+ channel signature sequence." <u>Biophys.J.</u> **66**(4): 1061-1067.

IO9. (2013). Retrieved 08-05, 2013, from <u>http://img.gawkerassets.com/img/18jpma2xnl0q8jpg/ku-xlarge.jpg</u>.

Kiryu, K., N. Machida, Y. Kashida, T. Yoshihara, A. Amada and T. Yamamoto (1999). "Pathologic and electrocardiographic findings in sudden cardiac death in racehorses." J <u>Vet Med Sci</u> **61**(8): 921-928.

Library, L. S. F. (2013). from http://www.bvfb.life.ku.dk/Default.aspx.

Lyle, C. H., G. Turley, K. J. Blissitt, R. S. Pirie, I. G. Mayhew, B. C. McGorum and J. A. Keen (2010). "Retrospective evaluation of episodic collapse in the horse in a referred population: 25 cases (1995-2009)." <u>J Vet Intern Med</u> **24**(6): 1498-1502.

Lyle, C. H., F. A. Uzal, B. C. McGorum, H. Aida, K. J. Blissitt, J. T. Case, J. T. Charles, I. Gardner, N. Horadagoda, K. Kusano, K. Lam, J. D. Pack, T. D. Parkin, R. F. Slocombe, B. D. Stewart and L. A. Boden (2011). "Sudden death in racing Thoroughbred horses: an international multicentre study of post mortem findings." <u>Equine Vet J</u> **43**(3): 324-331.

Nerbonne, J. M. and R. S. Kass (2005). "Molecular physiology of cardiac repolarization." <u>Physiol Rev.</u> **85**(4): 1205-1253.

Olander, E. (2012). <u>Action Potential Repolarization in the Equine Heart</u> Master's Thesis, University of Copenhagen.

Poulsen, A. N. and D. A. Klaerke (2007). "The KCNE1 beta-subunit exerts a transient effect on the KCNQ1 K+ channel." <u>Biochem Biophys Res Commun</u> **363**(1): 133-139.

Sanguinetti, M. C., M. E. Curran, A. Zou, J. Shen, P. S. Spector, D. L. Atkinson and M. T. Keating (1996). "Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel." <u>Nature</u> **384**(6604): 80-83.

Sanguinetti, M. C., C. Jiang, M. E. Curran and M. T. Keating (1995). "A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel." <u>Cell</u> **81**(2): 299-307.

Splawski, I., J. Shen, K. W. Timothy, M. H. Lehmann, S. Priori, J. L. Robinson, A. J. Moss, P. J. Schwartz, J. A. Towbin, G. M. Vincent and M. T. Keating (2000). "Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2." <u>Circulation</u> **102**(10): 1178-1185.

Tan, H. L., C. J. Hou, M. R. Lauer and R. J. Sung (1995). "Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes." <u>Ann Intern Med</u> **122**(9): 701-714.

Wang, Q., M. E. Curran, I. Splawski, T. C. Burn, J. M. Millholland, T. J. VanRaay, J. Shen, K. W. Timothy, G. M. Vincent, J. T. de, P. J. Schwartz, J. A. Toubin, A. J. Moss, D. L. Atkinson, G. M. Landes, T. D. Connors and M. T. Keating (1996). "Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias." <u>Nat.Genet.</u> **12**(1): 17-23.

Warmke, J. W. and B. Ganetzky (1994). "A family of potassium channel genes related to eag in Drosophila and mammals." <u>Proc.Natl.Acad.Sci.U.S.A</u> **91**(8): 3438-3442.

Weissenburger, J., M. Noyer, G. Cheymol and P. Jaillon (1999). "Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome." <u>Clin Exp Allergy</u> **29 Suppl 3**: 190-196.

Witchel, H. J., J. T. Milnes, J. S. Mitcheson and J. C. Hancox (2002). "Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes." <u>J Pharmacol Toxicol Methods</u> **48**(2): 65-80.

Appendices

Apendix I Primers used

Only the p-Xoom and Ambion primers were forward primers, the GSP's were reverse.

The user manual for the RACE kit specified that the primers were optimized for 60°C ±5°C

Ambion 5' RACE Primers:

Primer	Sequence $5' - 2'$	hn	Temperature	GC content	Sense
name	Sequence 5 – 5		remperature	oc content	strand
Inner	CGCGGATCCGAACACTGCGTTTGCTGGCTTTGAT	34	72,77°C	56%	N/A
Outer	GCTGATGGCGATGAATGAACACTG	24	61,55°C	50%	N/A

KCNQ1:

Primer 62	CAGCGCTTCCTCTCGGCCCT	20	65,27°C	70%	AGGGCCGAGAGGAAGCGCTG
Primer 63	GAGAAGGGGCACTTCTTGGCCAGG	24	64,17°C	63%	CCTGGCCAAGAAGTGCCCCTTCTC

KCNE1:

Primer 67	ACAGCTTGGCCAGAAAGGGC	20	60,18°C	60%	GCCCTTTCTGGCCAAGCTGT
Primer 68	CGGGCTGGGCTAGACGTG	18	60,38°C	72%	CACGTCTAGCCCAGCCCG

KCNE2:

K2 Inner	GCTCAGCTGTCGTGTTCCTGCGC	23	66,88°C	65%	GCGCAGGAACACGACAGCTGAGC

p-Xoom:

IVTF	CAGAGCTCTCTGGCTAACTAGAG	23	61,49°C	52%	N/A
------	-------------------------	----	---------	-----	-----

Apendix II KCNQ1

The Blue is what was found during this project, and the turquoise is putative.

Score 2593 b Query	its(1404	Expect Identitie 4) 0.0 1828/2 Aligence Contract Contra	:s)37(90%) GGCCGAGAGGAAGCGCTG	Gaps 12/2037(0%) GGGCTGGGGCCGCCTG	Strand Plus/Plus 60
Sbjct	1	ATGGCCGCGGCCTCCTCCCCGCCCAG	GGCCGAGAGGAAGCGCTG	 GGGTTGGGGCCGCCTG	60
Query	61	CCGGGCGCCCGGCGGGGCAGCGCGGG	CCTGGCCAAGAAGTGCCC	CTTCTCCCTGGAGCTG	120
Sbjct	61	CCAGGCGCCCGGCGGGGGCAGCGCGGG	CCTGGCCAAGAAGTGCCC	CTTCTCGCTGGAGCTG	120
Query	121	GCTGAGGGCGGCCCGGCGGGCGGCGC	GCTCTATGCGCCCATCGT	gcctcccggcacccag	180
Sbjct	121	GCGGAGGGCGGCCCGGCGGCGGCGCGC	GCTCTACGCGCCCATCG-	CGCCCGGCGCCCCA	177
Query	181	gggcccgcgctccccgcgtctccggc	cccgccggccgcgccccc	cgcagccgccgacctt	240
Sbjct	178	GGTCCCGCGCCCCCTGCGTCCCCGGC		CAGTTGCCTCCGACCTT	237
Query	241	ggcccgcggccgccggtgagcctcga	CCCGCGCGTCTCCATCTA	ACAGGACGCGCCGCCCG	300
Sbjct	238	GGCCCGCGGCCGCCGGTGAGCCTAGA	CCCGCGCGTCTCCATCTA	ACAGCACGCGCCGCCCG	297
Query	301	CTGCTCGCGCGCACCCACATCCAGGG	CCGCGTCTACAACTTCCI	CGAGCGCCCCACGGGC	360
Sbjct	298	GTGTTGGCGCGCACCCACGTCCAGGG	CCGCGTCTACAACTTCCT	CGAGCGTCCCACCGGC	357
Query	361	TGGAAGTGCTTCGTCTACCACTTCGC	AGTCTTCCTCATCGTCCT	GGCCTGCCTCATCTTC	420
Sbjct	358	TGGAAATGCTTCGTTTACCACTTCGC	CGTCTTCCTCATCGTCCI	GGTCTGCCTCATCTTC	417
Query	421	AGCGTGCTGTCTACCATCGAGCAGTA	IGTCACTCTGGCCACAGG	GACCCTCTTCTGGATG	480
Sbjct	418	AGCGTGCTGTCCACCATCGAGCAGTA	IGCCGCCCTGGCCACGGG	GACTCTCTTCTGGATG	477
Query	481	GAGATCGTCCTGGTGGTGTTCTTTGG	GACAGAGTACGCCGTCCG	GCCTCTGGTCAGCAGGC	540
Sbjct	478	GAGATCGTGCTGGTGGTGTTCTTCGG	GACGGAGTACGTGGTCCG	GCCTCTGGTCCGCCGGC	537
Query	541	TGCCGCAGCAAGTACGTGGGCATCTG	GGGGCGGCTGCGCTTTGC	CCCGGAAGCCCATTTCC	600
Sbjct	538	TGCCGCAGCAAGTACGTGGGCCTCTG	GGGCCGGCTGCGCTTTGC	CCCGGAAGCCCATTTCC	597
Query	601	ATCATTGACCTCATTGTGGTTGTGGC		CGTGGGCTCCAAAGGG	660
Sbjct	598	ATCATCGACCTCATCGTGGTCGTGGC	CTCCATGGTGGTCCTCTG	GCGTGGGCTCCAAGGGG	657
Query	661	CAGGTGTTTGCCACCTCAGCCATCAG	GGGCATCCGATTCCTTCA		720
Sbjct	658	CAGGTGTTTGCCACGTCGGCCATCAG	GGCATCCGCTTCCTGCA	AGATCCTGAGGATGCTA	717
Query	721	CATGTCGACCGCCAGGGAGGCACCTG	GAGGCTGCTGGGCTCCGI	GGTCTTCATCCACCGT	780
Sbjct	718	CACGTCGACCGCCAGGGAGGCACCTG	GAGGCTCCTGGGCTCCGI	GGTCTTCATCCACCGC	777
Query	781	CAGGAGCTGATAACCACCTTGTACAT	CGGCTTCCTGGGCCTCAI	CTTCTCCTCGTACTTC	840
Sbjct	778	CAGGAGCTGATAACCACCCTGTACAT	CGGCTTCCTGGGCCTCAT	CTTCTCCTCGTACTTT	837
Query	841	GTGTACCTGGCCGAGAAGGACGCCGT	GAACGAGTCGGGCCGTGI	CGAGTTTGGCAGCTAT	900
Sbjct	838	GTGTACCTGGCTGAGAAGGACGCGGT	GAACGAGTCAGGCCGCGI	GGAGTTCGGCAGCTAC	897

Query	901	GCAGATGCCCTTTGGTGGGGGGGTGGTCACTGTCACCACCATTGGCTATGGAGACAAAGTG	960
Sbjct	898	GCAGATGCGCTGTGGTGGGGGGGGGGGGGCACAGGTCACCACCACCATCGGCTATGGGGACAAGGTG	957
Query	961	CCCCAGACGTGGGTCGGGAAGACCATTGCCTCCTGCTTCTCCGTCTTCGCTATCTCCTTC	1020
Sbjct	958	CCCCAGACGTGGGTCGGGAAGACCATCGCCTCCTGCTTCTCTGTCTTTGCCATCTCCTTC	1017
Query	1021	TTCGCACTCCCGGCGGGGATCCTCGGCTCGGGCTTTGCCCTGAAGGTGCAGCAGAAACAG	1080
Sbjct	1018	TTTGCGCTCCCAGCGGGGATTCTTGGCTCGGGGTTTGCCCTGAAGGTGCAGCAGAAGCAG	1077
Query	1081	AGGCAGAAACACTTCAACCGGCAGATTCCGGCGGCAGCCTCGCTCATTCAGACGGCGTGG	1140
Sbjct	1078	AGGCAGAAGCACTTCAACCGGCAGATCCCGGCGGCAGCCTCACTCA	1137
Query	1141	AGGTGCTACGCAGCTGAGAATCCCGACTCCTCCACCTGGGAGATCTACGTGCGGAAGCCC	1200
Sbjct	1138	AGGTGCTATGCTGCCGAGAACCCCGACTCCTCCACCTGGAAGATCTACATCCGGAAGGCC	1197
Query	1201	TCCCGGAGCCACGCTCTGCTCTCCCCCAGCCCCAAGCCCAAGAAGTCTGCCATGGTAAAG	1260
Sbjct	1198	CCCCGGAGCCACACTCTGCTGTCACCCAGCCCCAAACCCAAGAAGTCTGTGGTGGTAAAG	1257
Query	1261		1320
Sbjct	1258	AAAAAAAAGTTCAAGCTGGACAAAGACAATGGGGTGACTCCTGGAGAGAAGATGCTCACA	1317
Query	1321	GTCCCTCACATCACGTGTGACCTCGTCTCGGAGGAGGCGGAGGCCAGACCATTTCTTGGTG	1380
Sbjct	1318	GTCCCCCATATCACGTGCGACC-CCCCAGAAGAGCGGCGGCTGGACCACTTCTCTGTC	1374
Query	1381	GAGAGCTGTGACAATTCTGTGAAGAAGAGGCCCCACGCTGCTAGAAGTGAGCACGGCCCAT	1440
Sbjct	1375	GACGGCTATGACAGTTCTGTAAGGAAGAGCCCAACACTGCTGGAAGTGAGCATGCCCCAT	1434
Query	1441	TTCATGAGAACCAACAGCTTTGCTGAGGACCTGGACCTGGAAGGGGAGACGCTGCTGGCT	1500
Sbjct	1435	TTCATGAGAACCAACAGCTTCGCCGAGGACCTGGACCTGGAAGGGGAGACTCTGCTGACA	1494
Query	1501		1560
Sbjct	1495	CCCATCACCCACATCTCACAGCTGCGGGAACACCATCGGGCCACCATTAAGGTCATTCGA	1554
Query	1561	CGCATGCAGTACTTTGTGGCCAAGAAGAAATTCCAGCAAGCGCGGAAGCCCTATGATGTG	1620
Sbjct	1555	CGCATGCAGTACTTTGTGGCCAAGAAGAAATTCCAGCAAGCGCGGAAGCCTTACGATGTG	1614
Query	1621	CGGGACGTCATTGAGCAGTACTCCCAGGGCCACCTCAACCTCATGGTGCGCATCAAAGAG	1680
Sbjct	1615	CGGGACGTCATTGAGCAGTACTCGCAGGGCCACCTCAACCTCATGGTGCGCATCAAGGAG	1674
Query	1681	CTGCAGAGAAGGCTGGACCAGTCCATCGGAAAGCCCTCCTCTTCATCTCCGGCTCAGAA	1740
Sbjct	1675	CTGCAGAGGAGGCTGGACCAGTCCATTGGGAAGCCCTCACTGTTCATCTCCGTCTCAGAA	1734
Query	1741	AAGAGCAAGGACCGCGGCAATAACACCATCGGCGCCCGCC	1800
Sbjct	1735	AAGAGCAAGGATCGCGGCAGCAACACGATCGGCGCCCGCC	1794
Query	1801	GTGACGCAGCTGGACCAGAGGCTGGTGCTCATCACAGACATGCTGCACCAGCTGCTCTCC	1860
Sbjct	1795	GTGACGCAGCTGGACCAGAGGCTGGCACTCATCACCGACATGCTTCACCAGCTGCTCTCC	1854

Query	1861	TTGCACCACGGCAGC-CCCCCGGGCGGCCGTCCCCCCAGCGGGGACGAGGCCCAAGTG	1917
Sbjct	1855	TTGCACGGTGGCAGCACCCCGGCAGCGGCGGCCCCCCAGAGAGGGGGGG	1914
Query	1918	GTCCAGCCCTGTGGTGGCGGCTCCATCAACCCCGAGCTCTTCCTGCCCAGCAACGCC	1974
Sbjct	1915	ACCCAGCCCTGCGGCAGTGGCGGCTCCGTCGACCCTGAGCTCTTCCTGCCCAGCAACACC	1974
Query	1975	CTGCCCACCTACGAACAGCTGACCGTGCCCCACAGGGGCCCTGACGAGGGGTCCTGA 203	31
Sbjct	1975	CTGCCCACCTACGAGCAGCTGACCGTGCCCAGGAGGGGCCCCGATGAGGGGTCCTGA 20	31

Protein BLAST

A yellow color indicates a site where a human mutation is noted either in ClinVar or at http://www.fsm.it/cardmoc/ only ones that were 0 – 1bp adjacent from dissimilarities have been marked

Red indicates when said mutation is the same as the human

A green color indicates the membrane spanning helices as calculated from TMHMM 2.0 server

Score		Expect Method	Identities	Positives	Gaps
1140 b	its(29	50) 0.0 Compositional matrix adjust.	614/678(91%)	631/678(93%)	4/678(0%)
Query	Ţ	MDAASSPPRAERKRWGWGRLPGARRGSAGLAKKCPF M AASSPPRAERKRWGWGRLPGARRGSAGLAKKCPF	'SLELAEGGPAGGALY. 'SLELAEGGPAGGALY	APIVPPGTQ 60 Apt p	
Sbjct	1	M <mark>A</mark> AASSPPRAERKRWGWGRLPGARRGSAGLAKKCPF	SLELAEGGPAGGALY.	APIAPGAPG 60	
Query	61	GPALPASPAPPAAPPAAADLGPRPVSLDPRVSIYF	TRRPLLARTHIQGRV	YNFLERPTG 120	
Sbjct	61	-PAPPASPAAPAAPPVASDLGPRPPVSLDPRVSII	TRRP+LARTH+QGRV TRRPVLARTHVQGRV	YNFLERPTG YNFLERPTG 119	
Query	121	WKCFVYHFAVFLIVLACLIFSVLSTIEQYVTLATG	LFWMEIVLVVFFGTE	<mark>Ya</mark> vrlwsag 180	
Sbjct	120	WKCFVYHFAVFLIVL CLIFSVLSTIEQY LATGI WKCFVYHFAVFLIV <mark>L</mark> V <mark>C</mark> LIFSVLSTIEQ <mark>Y</mark> AALATGI	'LFWMEIVLVVFFGTE 'LFWMEIVLVVFFGTE	y vrlwsag <mark>yv</mark> vrlwsag 179	
Query	181	CRSKYVGIWGRLRFARKP <mark>ISIIDLIVVVASMVVLC</mark> V	<mark>'GS</mark> KGQVFATSAIRGI	RFLQILRML 240	
Sbjct	180	CRSKYVG+WGRLRFARKPISIIDLIVVVASMVVLCV CRSKYV <mark>G</mark> LWGRLRFARKPISIIDLIVVVASMVVLCV	'GSKGQVFATSAIRGI: 'GSKGQVFATSAIRGI:	RFLQILRML RFLQILRML 239	
Query	241	HVDRQGGTWRLLGSVVFIHRQEL <mark>ITTLYIGFLGLI</mark>	<mark>'SSYFVYL</mark> AEKDAVNE	SGR <mark>VEFGSY</mark> 300	
Sbjct	240	HVDRQGGTWRLLGSVVFIHRQELITTLYIGFLGLIF HVDRQGGTWRLLGSVVFIHRQELITTLYIGFLGLIF	'SSYFVYLAEKDAVNE 'SSYFVYLAEKDAVNE	SGRVEFGSY SGRVEFGSY 299	
Query	301	ADALWWGVVTVTTIGYGDKVPQTWVGKTIAS <mark>CFSVE</mark>	AISFFALPAGILGSG	<mark>Fal</mark> kvqqkq 360	
Sbjct	300	ADALWWGVVTVTTIGYGDKVPQTWVGKTIASCFSVF ADALWWGVVTVTTIGYGDKVPQTWVGKTIASCFSVF	'AISFFALPAGILGSG 'AISFFALPAGILGSG	FALKVQQKQ FALKVQQKQ 359	
Query	361	RQKHFNRQIPAAASLIQTAWRCYAAENPDSSTW <mark>E</mark> IY	VRKPSRSHALLSPSP	KPKKSA <mark>M</mark> VK 420	
Sbjct	360	RQKHFNRQIPAAASLIQTAWRCYAAENPDSSTW+IY RQKHFNRQIPAAASLIQTAWRCYAAENPDSST <mark>WK</mark> IY	(+RK RSH LLSPSP) [] <mark>RK</mark> APRSHTLLSPSP	KPKKS +VK KPKKSV <mark>V</mark> VK 419	
Query	421	KKKFKLDKDNGVSPGEKTLTVPHITCDLV <mark>S</mark> EERRPI)HFLVE <mark>S</mark> CDNSVKKSP	TLLEVST <mark>A</mark> H 480	
Sbjct	420	KKKFKLDKDNGV+PGEK LTVPHITCD EERR D KKKFKLDKDNGVTPGEKMLTVPHITC <mark>D</mark> -P <mark>P</mark> EER <mark>R</mark> LD)HF V+ D+SV+KSP')HFSVD <mark>G</mark> YDSSVRKSP	TLLEVS H TLLEVSM <mark>P</mark> H 478	
Query	481	FMRTNSFAEDLDLEGETLLAPITHVSQLREHHRATI	KVIRRMQYFVAKKKF	QQARKPYDV 540	
Sbjct	479	FMRTNSFAEDLDLEGETLL PITH+SQLREHHRATI FMRTNSFAEDLDLEGETLLTPITHISQLREHHRATI	KVIRRMQYFVAKKKF KVIRRMQYFVAKKKF	QQARKPYDV QQARKPYDV 538	
Query	541	RDVIEQYSQGHLNLMVRIKELQRRLDQSIGKPSLFI	SGSEKSKDRGNNTIG	ARLNRVEDM 600	
Sbjct	539	RDVIEQYSQGHLNLMVRIKELQRRLDQSIGKPSLFI RDVIEQYSQGHLNLMVRIKELQRRLDQSIGKPSLFI	S SEKSKDRG+NTIG. SVSEKSKDRGS <mark>N</mark> TIG	ARLNRVED ARLNRVEDK 598	

Que	ery	601	VTQLDQRLVLITDMLHQLLSLHHGSPPGGRPPSGD- <mark>E</mark> AQVVQPCG-GGS <mark>A</mark> NPELFLPSNA 658	
Sb	jct	599	VTQLDQRL LITDMLHQLLSLH GS PG P + A + QPCG GGS++PELFLPSN VTQLDQRLALITDMLHQLLSLHGGSTP <mark>G</mark> SGGPPREG <mark>G</mark> AHITQPCGSGGS <mark>V</mark> DPELFLPSNT 658	
Que	ery	659	LPTYEQLTVPHRGPDEGS 676	
Sbj	jct	659	LPTYEQLTVPRRGPDEGS 676	
Equine 1		MDAASS	PPRAFRKRWGWGRI, PGARRGSAGI, AKKCPFSI, FI, AFGGPAGGAI, YAPTVPPGTOGPAI, PASPAPPAAPPAAADI,	80
Human 1	. 1	MAAASS	SPPRAERKRWGWGRLPGARRGSAGLAKKCPFSLELAEGGPAGGALYAPIAP-GAPGPAPPASPAAPAAPPVASDL	79
Equine 8	1	GPRPPV	SLDPRVSIYRTRRPLLARTHIQGRVYNFLERPTGWKCFVYHFAVFLIVLACLIFSVLSTIEQYVTLATGTLFWM	160
Human ₈	0	GPRPPV	VSLDPRVSIYSTRRPVLARTHVQGRVYNFLERPTGWKCFVYHFAVFLIVLVCLIFSVLSTIEQYAALATGTLFWM	159
Equine 1	61	EIVLVV	VFFGTEYAVRLWSAGCRSKYVGIWGRLRFARKPISIIDLIVVVASMVVLCVGSKGQVFATSAIRGIRFLQILRML	240
Human ₁	60	EIVLVV	YFFGTEY V VRLWSAGCRSKYVG L WGRLRFARKPISIIDLIVVVASMVVLCVGSKGQVFATSAIRGIRFLQILRML	239
Equine 2	41	HVDRQG	GTWRLLGSVVFIHRQELITTLYIGFLGLIFSSYFVYLAEKDAVNESGRVEFGSYADALWWGVVTVTTIGYGDKV	320
Human 2	40	HVDRQG	GTWRLLGSVVFIHRQELITTLYIGFLGLIFSSYFVYLAEKDAVNESGRVEFGSYADALWWGVVTVTTIGYGDKV	319
Equine 3	21	PQTWVG	KTIASCFSVFAISFFALPAGILGSGFALKVQQKQRQKHFNRQIPAAASLIQTAWRCYAAENPDSSTWEIY V RKP	400
Human 3	20	PQTWVG	KTIASCFSVFAISFFALPAGILGSGFALKVQQKQRQKHFNRQIPAAASLIQTAWRCYAAENPDSSTWKIYIRKA	399
Equine 4	01	SRSHAL	LSPSPKPKKSAMVKKKKFKLDKDNGVSPGEKTLTVPHITCDLVSEERRPDHFLVESCDNSVKKSPTLLEVSTAH	480
Human 4	00	PRSHTL	JSPSPKPKKSVVVKKKKFKLDKDNGVTPGEKMLTVPHITCD-PPEERRLDHFSVDGYDSSVRKSPTLLEVSMPH	478
Equine 4	81	FMRTNS	FAEDLDLEGETLL <mark>A</mark> PITH <mark>V</mark> SQLREHHRATIKVIRRMQYFVAKKKFQQARKPYDVRDVIEQYSQGHLNLMVRIKE	560
Human 4	79	FMRTNS	FAEDLDLEGETLLTPITHISQLREHHRATIKVIRRMQYFVAKKKFQQARKPYDVRDVIEQYSQGHLNLMVRIKE	558
Equine 5	61	LQRRLD	DQSIGKPSLFISGSEKSKDRGNNTIGARLNRVEDMVTQLDQRLVLITDMLHQLLSLHHGSPPG-GRPPSGDEAQV	639
Human 5	59	LQRRLD)QSIGKPSLFISVSEKSKDRGSNTIGARLNRVEDKVTQLDQRLALITDMLHQLLSLHGGSTPGSGGPPREGGAHI	638
Equine 6	40	VQPCG-	-GGSINPELFLPSNALPTYEQLTVPHRGPDEGS 676	
Human 6	39	TQPCGS	GGSVDPELFLPSNTLPTYEQLTVPRRGPDEGS 676	

Figure 9: A protein BLAST without any marking only indicating where there are differences in amino acids.

Apendix III KCNH2

Score 5055 b Query	its(273	Expect 7) 0.0 ATGCCGGTGCGGAGGGGCCA	Identities 3233/3480(93%) CGTCGCGCCGCAGAACACCTTCCT	Gaps 3/3480(0%) GGACACCATCATCCGC	Strand Plus/Plus
Sbjct	1	ATGCCGGTGCGGAGGGGCCA	CGTCGCGCCGCAGAACACCTTCCT		60
Query	61	AAGTTTGAGGGCCAGAGCCG	CAAGTTCATTATCGCCAACGCTCG	GGTGGAGAACTGCGCC	120
Sbjct	61	AAGTTTGAGGGCCAGAGCCG	TAAGTTCATCATCGCCAACGCTCG	GGTGGAGAACTGCGCC	120
Query	121	GTCATCTACTGCAACGACGG	CTTCTGCGAGCTGTGCGGCTACTC	GCGGGCCGAGGTGATG	180
Sbjct	121	GTCATCTACTGCAACGACGG	CTTCTGCGAGCTGTGCGGCTACTC	GCGGGCCGAGGTGATG	180
Query	181	CAGCGGCCCTGCACCTGCGA	CTTCCTGCACGGgccgcgcacgca		240
Sbjct	181	CAGCGACCCTGCACCTGCGA	CTTCCTGCACGGGCCGCGCACGCA	GCGCCGCGCTGCCGCG	240
Query	241	cagatcgcgcaGGCCTTGCT	GGGCGCCGAGGAGCGCAAAGTGGA	GATCTCCTTCTACCGG	300
Sbjct	241	CAGATCGCGCAGGCACTGCT	GGGCGCCGAGGAGCGCAAAGTGGA	AATCGCCTTCTACCGG	300
Query	301	AAGGATGGGAGCTGCTTCCT	GTGCCTGGTGGATGTGGTGCCCGT	GAAGAACGAGGATGGG	360
Sbjct	301	AAAGATGGGAGCTGCTTCCT	ATGTCTGGTGGATGTGGTGCCCGT	GAAGAACGAGGATGGG	360
Query	361	GCTGTCATCATGTTCATCCT		GGACATGGTGGGGTCC	420
Sbjct	361	GCTGTCATCATGTTCATCCT	CAATTTCGAGGTGGTGATGGAGAA	GGACATGGTGGGGTCC	420
Query	421	CCGGCCCGGGACACCAATCA	CCGTGGCCCCCCCCTAGCTGGCT	GGCCACAGGTCGGGCC	480
Sbjct	421	CCGGCTCATGACACCAACCA	CCGGGGCCCCCCCACCAGCTGGCT	GGCCCCAGGCCGCGCC	480
Query	481	AAGACCTTCCGCCTGAAGTT	GCCTGCGCTGCTGGCCTTGACAGC	GCGGGAGTCGACAGTG	540
Sbjct	481	AAGACCTTCCGCCTGAAGCT	GCCCGCGCTGCTGGCGCTGACGGC	CCGGGAGTCGTCGGTG	540
Query	541	CGGCCAGGTGGCGCGGGCAG	CACGGGGGCCCCCGGGGCTGTGGT	GGTGGACGTGGACCTG	600
Sbjct	541	CGGTCGGGCGGCGCGGGCGG	CGCGGGCGCCCCGGGGGCCGTGGT	GGTGGACGTGGACCTG	600
Query	601	ACGCCTGCGGCGCCCAGCAG	CGAGTCGCTGGCCCTGGACGAGGT	GACAGCCATGGACAAC	660
Sbjct	601	ACGCCCGCGGCACCCAGCAG	CGAGTCGCTGGCCCTGGACGAAGT	GACAGCCATGGACAAC	660
Query	661	CACGTGGCGGGGGCTTGGGCC	GGCGGAAGAGCGCCGCGCGCGCTGGT	GGGCCCCGGCTCGCCG	720
Sbjct	661	CACGTGGCAGGGCTCGGGCC	CGCGGAGGAGCGGCGTGCGCTGGT	GGGTCCCGGCTCTCCG	720
Query	721	CCCGCCTGTGCGCCCATCCC	GCACCCGTCACCCGGGCCCACAG	CCTCAACCCCGACGCC	780
Sbjct	721	CCCCGCAGCGCGCCCGGCCA	GCTCCCATCGCCCCGGGCGCGCACAG	CCTCAACCCCGACGCC	780
Query	781		GGCCCGGACACGCTCCCGGGAGAG	CTGTGCCAGCGTGCGC	840
Sbjct	781	TCGGGCTCCAGCTGCAGCCT	GGCCCGGACGCGCTCCCGAGAAAG	CTGCGCCAGCGTGCGC	840
Query	841	CGCGCCTCATCAGCGGATGA	CATCGAGGCCATGCGCACCGG	GCTGCCCCCACCGCCA	897
Sbjct	841	CGCGCCTCGTCGGCCGACGA	CATCGAGGCCATGCGCGCCGGGGI	GCTGCCCCCGCCACCG	900

Query	898	CGCCATGCCAGCACAGGGGCCATGCACCCCTGCGCAGCGGCCTGCTTAACTCCACATCA	957
Sbjct	901	CGCCACGCCAGCACCGGGGCCATGCACCCACTGCGCAGCGGCTTGCTCAACTCCACCTCG	960
Query	958	GATTCGGACCTCGTGCGCTACCGCACCATTAGCAAGATTCCCCCAAATCACCCTCAACTT	1017
Sbjct	961	GACTCCGACCTCGTGCGCTACCGCACCATTAGCAAGATTCCCCCAAATCACCCTCAACTTT	1020
Query	1018	GTGGACCTCAAGGGCGACCCCTTCCTGGCTTCGCCCACCAGTGACCGGGAGATCATAGCA	1077
Sbjct	1021	GTGGACCTCAAGGGCGACCCCTTCTTGGCTTCGCCCACCAGTGACCGTGAGATCATAGCA	1080
Query	1078	CCCAAGATAAAGGAGCGGACCCACAATGTCACCGAGAAGGTCACCCAGGTCCTGTCTCTG	1137
Sbjct	1081	CCTAAGATAAAGGAGCGAACCCACAATGTCACTGAGAAGGTCACCCAGGTCCTGTCCCTG	1140
Query	1138	GGTGCTGATGTGCTGCCGGAGTACAAGCTGCAGGCGCCACGCATCCACCGCTGGACCATC	1197
Sbjct	1141	GGCGCCGACGTGCTGCCTGAGTACAAGCTGCAGGCACCGCGCATCCACCGCTGGACCATC	1200
Query	1198	CTGCACTACAGCCCCTTCAAGGCCGTGTGGGACTGGCTCATCCTGCTGGTGGTCATCTAC	1257
Sbjct	1201	CTGCATTACAGCCCCTTCAAGGCCGTGTGGGACTGGCTCATCCTGCTGGTCATCTAC	1260
Query	1258	ACGGCCGTCTTCACGCCTACTCCGGCTGCCTTCCTGCTGAAGGAGAGGGCGCCC	1317
Sbjct	1261	ACGGCTGTCTTCACACCCTACTCGGCTGCCTTCCTGCTGAAGGAGGCCGGAAGAAGGCCCG	1320
Query	1318	CCGGCCACCGACTGTGGCTATGCCTGCCAGCCCTGGCAGTGGTGGACCTCATCGTGGAT	1377
Sbjct	1321	CCTGCTACCGAGTGTGGCTACGCCTGCCAGCCGCTGGCTG	1380
Query	1378	ATCATGTTCATCGTGGACATCCTCATCAACTTCCGCACCACCTATGTCAATGCCAACGAG	1437
Sbjct	1381	ATCATGTTCATTGTGGACATCCTCATCAACTTCCGCACCACCTACGTCAATGCCAACGAG	1440
Query	1438	GAGGTGGTCAGCCACCCTGGCCGCATCGCCGTCCACTACTTCAAGGGCTGGTTCCTCATC	1497
Sbjct	1441	GAGGTGGTCAGCCACCCGGCCGCATCGCCGTCCACTACTTCAAGGGCTGGTTCCTCATC	1500
Query	1498	GACATGGTGGCTGCCATCCCCTTTGACCTGCTCATCTTCGGTTCTGGCTCTGAGGAGCTG	1557
Sbjct	1501	GACATGGTGGCCGCCATCCCCTTCGACCTGCTCATCTTCGGCTCTGGCTCTGAGGAGCTG	1560
Query	1558	ATCGGGCTCCTGAAGACGGCGCGGCGGCTGCTGCGACTGGTGCGCGCGC	1617
Sbjct	1561	ATCGGGCTGCTGAAGACTGCGCGGCGGCTGCTGCGGCGCGGGGGGGG	1620
Query	1618	CGCTACTCGGAGTACGGGGCAGCGGTGCTCTTCCTGCTCATGTGCACCTTTGCGCTCATC	1677
Sbjct	1621	CGCTACTCAGAGTACGGCGCGGCCGTGCTGTTCTTGCTCATGTGCACCTTTGCGCTCATC	1680
Query	1678	GCGCACTGGCTGGCTTGCATCTGGTACGCCATCGGCAACATGGAGCAGCCGCACATGGAC	1737
Sbjct	1681	GCGCACTGGCTAGCCTGCATCTGGTACGCCATCGGCAACATGGAGCAGCCACACATGGAC	1740
Query	1738	TCCCGCATCGGCTGGCTGCACAACCTGGGCGACCAGATCGGCAAGCCCTACAACAGCAGT	1797
Sbjct	1741	TCACGCATCGGCTGGCTGCACAACCTGGGCGACCAGATAGGCAAACCCTACAACAGCAGC	1800
Query	1798	GGCCTGGGTGGCCCGTCCATCAAGGACAAGTATGTCACGGCCCTCTACTTCACCTTCAGC	1857
Sbjct	1801	GGCCTGGGCGGCCCCTCCATCAAGGACAAGTATGTGACGGCGCTCTACTTCACCTTCAGC	1860

Query	1858	AGCCTCACTAGCGTGGGCTTCGGCAATGTCTCCCCCAACACCAACTCAGAGAAGATCTTC	1917
Sbjct	1861	AGCCTCACCAGTGTGGGCTTCGGCAACGTCTCTCCCAACACCAACTCAGAGAAGATCTTC	1920
Query	1918	TCCATTTGTGTCATGCTCATTGGCTCCCTCATGTACGCCAGCATCTTTGGCAACGTGTCA	1977
Sbjct	1921	TCCATCTGCGTCATGCTCATTGGCTCCCTCATGTATGCTAGCATCTTCGGCAACGTGTCG	1980
Query	1978	GCCATCATCCAGCGGCTATACTCGGGCACAGCCCGCTACCACACGCAAATGCTCCGGGTG	2037
Sbjct	1981	GCCATCATCCAGCGGCTGTACTCGGGCACAGCCCGCTACCACACAGATGCTGCGGGTG	2040
Query	2038	CGGGAGTTCATCCGCTTCCACCAGATCCCTAACCCGCTGCGCCAGCGCCTTGAGGAGTAT	2097
Sbjct	2041	CGGGAGTTCATCCGCTTCCACCAGATCCCCAATCCCCTGCGCCAGCGCCTCGAGGAGTAC	2100
Query	2098	TTCCAGCACGCCTGGTCCTACACCAACGGCATCGACATGAACGCGGTGCTGAAGGGCTTC	2157
Sbjct	2101	TTCCAGCACGCCTGGTCCTACACCAACGGCATCGACATGAACGCGGTGCTGAAGGGCTTC	2160
Query	2158	CCGGAGTGCCTGCAGGCAGACATCTGCCTGCACCTGAACCGCTCGCT	2217
Sbjct	2161	CCTGAGTGCCTGCAGGCTGACATCTGCCTGCACCTGAACCGCTCACTGCTGCAGCACTGC	2220
Query	2218	AAGCCCTTCCGAGGGGCCACCAAAGGCTGCCTGCGGGCCCTGGCCATGAAGTTCAAGACG	2277
Sbjct	2221	AAACCCTTCCGAGGGGCCACCAAGGGCTGCCTTCGGGCCCTGGCCATGAAGTTCAAGACC	2280
Query	2278	ACACACGCACCGCCAGGGGACACGCTGGTGCACGCCGGGGACCTGCTCACCGCCCTCTAC	2337
Sbjct	2281	ACACATGCACCGCCAGGGGACACACTGGTGCATGCTGGGGGACCTGCTCACCGCCCTGTAC	2340
Query	2338	TTCATCTCCCGGGGCTCCATCGAGATCCTGCGGGGGCGATGTCGTCGTGGCCATCCTGGGG	2397
Sbjct	2341	TTCATCTCCCGGGGCTCCATCGAGATCCTGCGGGGCGACGTCGTCGTGGCCATCCTGGGG	2400
Query	2398	AAGAATGACATCTTCGGAGAGCCTCTGAACCTGTATGCGCGGCCTGGCAAGTCCAATGGG	2457
Sbjct	2401	AAGAATGACATCTTTGGGGAGCCTCTGAACCTGTATGCAAGGCCTGGCAAGTCGAACGGG	2460
Query	2458	GATGTGCGGGCCCTCACCTACTGCGACCTGCACAAGATCCACCGGGACGACCTGCTGGAG	2517
Sbjct	2461	GATGTGCGGGCCCTCACCTACTGTGACCTACACAAGATCCATCGGGACGACCTGCTGGAG	2520
Query	2518	GTGCTGGACATGTACCCCGAGTTCTCCGACCACTTCTGGTCCAGCCTGGAGATCACCTTC	2577
Sbjct	2521	GTGCTGGACATGTACCCTGAGTTCTCCGACCACTTCTGGTCCAGCCTGGAGATCACCTTC	2580
Query	2578	AACCTTCGAGACACCAACATGATCCCCGGCTCTCCCGGCAGCACAGAGCTGGAGGGCGGC	2637
Sbjct	2581	AACCTGCGAGATACCAACATGATCCCGGGCTCCCCCGGCAGTACGGAGTTAGAGGGTGGC	2640
Query	2638	TTCAACCGGCAACGCAAGCGCAAGCTGTCCTTCCGCAGACGCACCGACAAGGACCCGGAA	2697
Sbjct	2641	TTCAGTCGGCAACGCAAGCGCAAGTTGTCCTTCCGCAGGCGCACGGACAAGGACACGGAG	2700
Query	2698	CAgccaggggaggtgtcggccttggggccgggccgggggggg	2757
Sbjct	2701	CAGCCAGGGGAGGTGTCGGCCTTGGGGCCGGGCCGGGCGGG	2760
Query	2758	ggccggccagggggcccgtggggggAAAGCCCGTCCAGTGGCCCCTCCAGCCCTGAGAGC	2817
Sbjct	2761	GGCCGGCCGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	2820

Query	2818	AGTGAGGATGAGGGCCCAGGCCGCAGCTCCAGCCCCTCCGCCTGGTGCCCTTCTCCAGC	2877
Sbjct	2821	AGTGAGGATGAGGGCCCAGGCCGCAGCTCCAGCCCCTCCGCCTGGTGCCCTTCTCCAGC	2880
Query	2878	CCCAGGCCCCCGGAGAGCCGCCGGGTGGGGAGCCCCTGATTGAGGACTGCGAGAAGAGC	2937
Sbjct	2881	CCCAGGCCCCCGGAGAGCCGCCGGGTGGGGAGCCCCTGATGGAGGACTGCGAGAAGAGC	2940
Query	2938	AGTGACACATGTAACCCGCTGTCAGGCGCCTTCTCGGGAGTGTCCAACATCTTCAGCTTC	2997
Sbjct	2941	AGCGACACTTGCAACCCCCTGTCAGGCGCCTTCTCAGGAGTGTCCAACATTTTCAGCTTC	3000
Query	2998	TGGGGGGATAGTCGGGGCCGCCAGTACCAGGAGCTGCCTCGCTGccccgcccccgccccc	3057
Sbjct	3001	TGGGGGGACAGTCGGGGCCGCCAGTACCAGGAGCTCCCTCGATGCCCCGCCCCCACCCCC	3060
Query	3058	AGCCTCCTCAACATCCCTCTTTCCAGCCCTGGCCGGCGGCCGGGGGGGG	3117
Sbjct	3061	AGCCTCCTCAACATCCCCCTCTCCAGCCCGGGTCGGCGGCCCCGGGGCGACGTGGAGAGC	3120
Query	3118	AGGCTGGACGCCCTTCAGAGGCAGCTTAACAGGCTGGAGACGCGGCTGAGTGCAGACATG	3177
Sbjct	3121	AGGCTGGATGCCCTCCAGCGCCAGCTCAACAGGCTGGAGACCCGGCTGAGTGCAGACATG	3180
Query	3178	GCCACCGTCCTGCAGCTACTGCAGAGACAGATGACACTGGTCCCTCCAGCCTACAGTGCT	3237
Sbjct	3181	GCCACTGTCCTGCAGCTGCTACAGAGGCAGATGACGCTGGTCCCGCCCG	3240
Query	3238	GTGACCACCCCGGGGCCCGGCCCCACCTCCACCTCCCCTCTCCTGCCTG	3297
Sbjct	3241	GTGACCACCCCGGGGCCTGGCCCCACTTCCACATCCCCGCTGTTGCCCGTCAGCCCCCTC	3300
Query	3298	CCCACTCTCACCCTGGATTCGCTTTCTCAGGTTTCCCAGTTCATGGCGTGCGAGGAGCTC	3357
Sbjct	3301	CCCACCCTCACCTTGGACTCGCTTTCTCAGGTTTCCCAGTTCATGGCGTGTGAGGAGCTG	3360
Query	3358	CCTCCGGGGGCCCCAGAGCTTCCCCAAGACGGCCCCACTCGACGCCTCTCCCTGCCGGGC	3417
Sbjct	3361	CCCCCGGGGGGCCCCAGAGCTTCCCCAAGAAGGCCCCACACGACGCCTCTCCCTACCGGGC	3420
Query	3418	CAGCTGGGGGGCCCTCACCTCCCAGCCCTGCACAGACACGGCTCAGACCCGGGCAGTTAG	3477
Sbjct	3421	CAGCTGGGGGGCCCTCACCTCCCAGCCCTGCACAGACACGGCTCGGACCCGGGCAGTTAG	3480

Protein BLAST

The TMHMM gave only 4 highly probable helices both for human and equine proteins. There were no dissimilarities between the first and the last trans membrane helix in the entire segment, 408bp to 661bp so the graphic is left out.

Score 2208 bit	ts(5721	Expect .) 0.0	Method Compositional matrix adjust.	Identities 1138/1159(98%)	Positives 1145/1159(98 ⁰	Gaps %) 1/1159(0%)
Query	1	MPVRRGHV MPVRRGHV	VAPQNTFLDTIIRKFEGQSRKFIIAN VAPQNTFLDTIIRKFEGQSRKFIIAN	ARVENCAVIYCNDGFC ARVENCAVIYCNDGFC	ELCGYSRAEVM ELCGYSRAEVM	60
Sbjct	1	MPVRRGHV	YAPQNTFLDTIIRKFEGQSRKFIIAN	ARVENCAVIYCNDGFC	ELCGYSRAEVM	60
Query	61	QRPCTCDF QRPCTCDF	LHGPRTQRRAAAQIAQALLGAEERK LHGPRTQRRAAAQIAQALLGAEERK	VEISFYRKDGSCFLCL VEI+FYRKDGSCFLCL	VDVVPVKNEDG VDVVPVKNEDG	120
Sbjct	61	QRPCTCDF	LHGPRTQRRAAAQIAQALLGAEERK	VE <mark>I</mark> AFYRKDGSCFLCL	VDVVPVKNEDG	120
Query	121	AVIMFILN AVIMFILN	IFEVVMEKDMVGSPARDTNHRGPPTS IFEVVMEKDMVGSPA DTNHRGPPTS	WLATGRAKTFRLKLPA WLA GRAKTFRLKLPA	LLALTARESTV LLALTARES+V	180
Sbjct	121	AVIMFILN	IFEVVMEKDMVGSPAHDTNHRGPPTS	WLAPGRAKTFRLKLPA	LLALTARESSV	180

Query	181	RPGGAGSTGAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSP	240
Sbjct	181	R GGAG GAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSP RSGGAGGAGAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSP	240
Query	241	PACAPIPHPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRTG-LPPPP	299
Sbjct	241	PRSAPGQLPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRAGVLPPPP	300
Query	300	RHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIA RHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIA	359
Sbjct	301	RHASTGAMHPLRSGLLNSTSDSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIA	360
Query	360	PKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIY PKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIY	419
Sbjct	361	PKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTILHYSPFKAVWDWLILLLVIY	420
Query	420	TAVFTPYSAAFLLKETEEGPPATDCGYACQPLAVVDLIVDIMFIVDILINFRTTYVNANE TAVFTPYSAAFLLKETEEGPPAT+CGYACOPLAVVDLIVDIMFIVDILINFRTTYVNANE	479
Sbjct	421	TAVFTPYSAAFLLKETEEGPPATECGYACQPLAVVDLIVDIMFIVDILINFRTTYVNANE	480
Query	480	EVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLD EVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLD	539
Sbjct	481	EVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLD	540
Query	540	RYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSS RYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEOPHMDSRIGWLHNLGDOIGKPYNSS	599
Sbjct	541	RYSEYGAAVLFLLMCTFALIAHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSS	600
Query	600	GLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFGNVS GLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFGNVS	659
Sbjct	601	GLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIFSICVMLIGSLMYASIFGNVS	660
Query	660	AIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGF AIIORLYSGTARYHTOMLRVREFIRFHOIPNPLRORLEEYFOHAWSYTNGIDMNAVLKGF	719
Sbjct	661	AIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGF	720
Query	720	PECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALY PECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALY	779
Sbjct	721	PECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALY	780
Query	780	FISRGSIEILRGDVVVAILGKNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLE FISRGSIEILRGDVVVAILGKNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLE	839
Sbjct	781	FISRGSIEILRGDVVVAILGKNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLE	840
Query	840	VLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGGFNRQRKRKLSFRRRTDKDPE VLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGGF+RORKRKLSFRRRTDKD E	899
Sbjct	841	VLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGGFSRQRKRKLSFRRTDKDTE	900
Query	900	QPGEVSALGPGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSS OPGEVSALGPGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSS	959
Sbjct	901	QPGEVSALGPGRAGAGPSSRGRPGGPWGESPSSGPSSPESSEDEGPGRSSSPLRLVPFSS	960
Query	960	PRPPGEPPGGEPLIEDCEKSSDTCNPLSGAFSGVSNIFSFWGDSRGRQYQELPRCPAPAP PRPPGEPPGGEPL+EDCEKSSDTCNPLSGAFSGVSNIFSFWGDSRGROYOELPRCPAP	1019
Sbjct	961	PRPPGEPPGGEPLMEDCEKSSDTCNPLSGAFSGVSNIFSFWGDSRGRQYQELPRCPAPTP	1020
Query	1020	SLLNIPLSSPGRRPRGDVESRLDALQRQLNRLETRLSADMATVLQLLQRQMTLVPPAYSA SLLNIPLSSPGRRPRGDVESRLDALOROLNRLETRLSADMATVLOLLOROMTLVPPAYSA	1079
Sbjct	1021	SLLNIPLSSPGRRPRGDVESRLDALQRQLNRLETRLSADMATVLQLLQRQMTLVPPAYSA	1080
Query	1080	VTTPGPGPTSTSPLLPVSPIPTLTLDSLSQVSQFMACEELPPGAPELPQDGPTRRLSLPG VTTPGPGPTSTSPLLPVSP+PTLTLDSLSQVSQFMACEELPPGAPELPQ+GPTRRLSLPG	1139
Sbjct	1081	VTTPGPGPTSTSPLLPVSPLPTLTLDSLSQVSQFMACEELPPGAPELPQEGPTRRLSLPG	1140

Equine	1	${\tt MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCELCGYSRAEVMQRPCTCDFLHGPRTQRRAAA}$	80
Human	1	${\tt MPVRRGHVAPQNTFLDTIIRKFEGQSRKFIIANARVENCAVIYCNDGFCELCGYSRAEVMQRPCTCDFLHGPRTQRRAAA}$	80
Sbj			
Equine	81	$\verb"QIAQALLGAEERKVEISFYRKDGSCFLCLVDVVPVKNEDGAVIMFILNFEVVMEKDMVGSPARDTNHRGPPTSWLATGRA"$	160
Human	81	$\verb"QIAQALLGAEERKVEIAFYRKDGSCFLCLVDVVPVKNEDGAVIMFILNFEVVMEKDMVGSPAHDTNHRGPPTSWLAPGRA$	160
Equine	161	$\tt KTFRLKLPALLALTARES {\tt TVRP} {\tt GGAG} {\tt ST} {\tt GAPGAVVVDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSP$	240
Human	161	$\tt KTFRLKLPALLALTARES {\tt SVR}{\tt S} {\tt GGAG} {\tt GA} {\tt GAPGAVVV} {\tt VDVDLTPAAPSSESLALDEVTAMDNHVAGLGPAEERRALVGPGSP$	240
Equine	241	PACAPIPHPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRTG-LPPPPRHASTGAMHPLRSGLLNSTS	319
Human	241	PRSAPGQLPSPRAHSLNPDASGSSCSLARTRSRESCASVRRASSADDIEAMRAGVLPPPPRHASTGAMHPLRSGLLNSTS	320
Equine	320	DSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIAPKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTI	399
Human	321	DSDLVRYRTISKIPQITLNFVDLKGDPFLASPTSDREIIAPKIKERTHNVTEKVTQVLSLGADVLPEYKLQAPRIHRWTI	400
E au dia a	400	I UVODEVALENDATI TI TI TUTVTALIETDVOA SET TVETERODDATDOOVACADI ALEDI TUDIVETUDI TI TVEDTVO DIANE	470
Equine	400		4/9
Tuman	401	LHISPERAVWDWLILLLVIIIAVEIPISAAFLLKEIEEGPPAIECGIACQPLAVVDLIVDIMEIVDILINERIIIVNANE	460
Equine	480	EVVSHPGRIAVHYFKGWFLIDMVAAIPFDLLIFGSGSEELIGLLKTARLLRLVRVARKLDRYSEYGAAVLFLLMCTFALI	559
Human	481	EVVSHPGRTAVHYFKGWFLTDMVAATPFDLLTFGSGSEELTGLLKTARLERLVRVARKLDRYSEYGAAVLFLLMCTFALT	560
Equine	560	AHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSSGLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIF	639
Human	561	AHWLACIWYAIGNMEQPHMDSRIGWLHNLGDQIGKPYNSSGLGGPSIKDKYVTALYFTFSSLTSVGFGNVSPNTNSEKIF	640
Equine	640	${\tt SICVMLIGSLMYASIFGNVSAIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGF}$	719
Human	641	${\tt SICVMLIGSLMYASIFGNVSAIIQRLYSGTARYHTQMLRVREFIRFHQIPNPLRQRLEEYFQHAWSYTNGIDMNAVLKGF}$	720
Equine	720	PECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALYFISRGSIEILRGDVVVAILG	799
Human	721	PECLQADICLHLNRSLLQHCKPFRGATKGCLRALAMKFKTTHAPPGDTLVHAGDLLTALYFISRGSIEILRGDVVVAILG	800
Equine	800	KNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLEVLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGG	879
Human	801	KNDIFGEPLNLYARPGKSNGDVRALTYCDLHKIHRDDLLEVLDMYPEFSDHFWSSLEITFNLRDTNMIPGSPGSTELEGG	880
Equipo	960	PD DDGF DDGGF DI TEDGFKSSDTCHDI SGAFSGVSNIFSFWGDSDGDOVOFI DDCDADADSI I NI DI SSDGDD DDGDVFS	1030
Equille Human	961	DD DDGE DDGGE DI MEDGENSSDI GNEDSGE SGAFSGASSNI ESEWGDSDGDOVOFI DDGDA DTDSI I NI DI SSDGDD DDGDAFS	1035
inannann	501	PREPOLEFOGLELMEDCERSSDICAELSONICISEMODSKORVIVELERCERETESLEATELSSFORRERODVES	1040
Fauine	1040	RLDALOROLNRLETRLSADMATVLOLLOROMTLVPPAYSAVTTPGPGPTSTSPLLPVSPIPTLTLDSLSOVSOFMACEEL	1119
Human	1041	RLDALOROLNRLETRLSADMATVLOLLOROMTLVPPAYSAVTTPGPGPTSTSPLLPVSPLPTLTLDSLSOVSOFMACEEL	1120
Equine	1120	PPGAPELPQDGPTRRLSLPGQLGALTSQPLHRHGSDPGS 1158	
Human	1121	PPGAPELPQEGPTRRLSLPGQLGALTSQPLHRHGSDPGS 1159	

Figure 10: A protein BLAST without any marking only indicating where there are differences in amino acids.

Apendix IV KCNE1

Score		Expect Ide	entities	Gaps	Strand
399 bits	s(216)	6e-116 33	3/391(85%)	2/391(0%)	Plus/Plus
Query	1	ATGATCCTGTCTAACACCACAGCT	GTGATGCCCTTTCTGGCCAAG	CTGTGGCAGGGGACA	60
Sbjct	1	ATGATCCTGTCTAACACCACAGCG	GTGACGCCCTTTCTGACCAAG	CTGTGGCAGGAGACA	60
Query	61	GTTCAACAGGGCAGCAACACGTCT	AGCCCAGCCCGCAGGTCCCCC	AGCAACGAG-GACGG	119
Sbjct	61	GTTCAGCAGGGTGGCAACATGTCG	GGCCTGGCCCGCAGGTCCCCC	CGCAGC-AGTGACGG	119
Query	120	CAAGCTTGAGGCACTCTACATTCT	CATGGTGCTTGGCTTCTTCGG	CTTCTTCACCCTGGG	179
Sbjct	120	CAAGCTGGAGGCCCTCTACGTCCT	CATGGTACTGGGATTCTTCGG	CTTCTTCACCCTGGG	179
Query	180	CATCATGCTGAGTTACATCCGCTC		CGACCCATTCAATGT	239
Sbjct	180	CATCATGCTGAGCTACATCCGCTC	CAAGAAGCTGGAGCACTCGAA	CGACCCATTCAACGT	239
Query	240	GTACATCGAGTCTGACACCTGGCA		CCAGTCCCGGATTCT	299
Sbjct	240	CTACATCGAGTCCGATGCCTGGCA	AGAGAAGGACAAGGCCTATGT	CCAGGCCCGGGTCCT	299
Query	300	GGAGAGCTACAGGGCGTGTTATGT	CATTGAAAACGAGCTGGCTGT	GGAACAGCCAGGCAC	359
Sbjct	300	GGAGAGCTACAGGTCGTGCTATGT	CGTTGAAAACCATCTGGCCAT	AGAACAACCCAACAC	359
Query	360	ATACCTTCCTGAGATGGACCCTTC	CATCATGA 390		
Sbjct	360	ACACCTTCCTGAGACGAAGCCTTC	CCCCATGA 390		

Protein BLAST

Score	Expect Method	Identities	Positives	Gaps
222 bits(566)) 5e-80 Compositional matrix adjust.	103/128(80%)	112/128(87%)	0/128(0%)
Query 1	MILSNTTAVMPFLAKLWQGTVQQGSNTSSPARRS MILSNTTAV PFL KLWQ TVQQG N S ARRS	SP <mark>S</mark> N <mark>E</mark> DGKLEA <mark>LYILMV</mark> SP + DGKLEALY+LMV	<mark>LGFFGFFTLG</mark> 60 LGFFGFFTLG	
Sbjct 1	MILSNTTAVTPFLTKLWQETVQQGGNM <mark>S</mark> GLARRS	SP <mark>R</mark> S <mark>S</mark> DGKLEALY <mark>V</mark> LMV	LGFFGFFTLG 60	
Query 61	IMLSYIRSKKLEHSHDPFNVYIESDTWQEKDKK IMLSYIRSKKLEHS+DPFNVYIESD WQEKDK	/FQSRILESYRACYV <mark>I</mark> E / Q+R+LESYR+CYV+E	NELAVEQPGT 120 N LA+EQP T)
Sbjct 61	IMLSYIRSKKLEH <mark>S</mark> N <mark>D</mark> PFNVYIES <mark>D</mark> A <mark>W</mark> QEKDKA	YVQA <mark>R</mark> VLESYRSCYV <mark>V</mark> E	NHLAIEQPNT 120)
Query 121	YLPEMDPS 128 +LPE PS			
Sbjct 121	HLPETK <mark>P</mark> S 128			

Equine 1 Human 1	MILSNTTAVMPFLAKLWQGTVQQGSNTSSPARRSPSNEDGKLEALYILMV MILSNTTAVTPFLTKLWQETVQQGGNMSGLARRSPRSSDGKLEALYVLMV	LGFFGFFTLGIMLSYIRSKKLEHS <mark>H</mark> DPFNV LGFFGFFTLGIMLSYIRSKKLEHS <mark>N</mark> DPFNV	80 80
Equine 81	YIESDTWQEKDKKYFQSRILESYRACYVIENELAVEQPGTYLPEMDPSS	129	
Human 81	YIESDAWQEKDKAYVQARVLESYRSCYVVENHLAIEQPNTHLPETKPSP	129	

Figure 11: A protein BLAST without any marking only indicating where there are differences in amino acids.

Apendix V KCNE2

The first 7bp and the last 3bp (turquoise) are putative based on the predicted equine sequence XM_001494194.1

Score 459 bits	s(508)	Expect Ident 7e-134 325/3	ities 372(87%)	Gaps 0/372(0%)	Strand Plus/Plus
Query	1	ATGCCCACTTTATCCAATTTGACACA	GACCCTGGAAGATGTCTTC.		60
SDJCL	T	AIGICIACIIIAICCAAIIICACACA	JACGCIGGAAGACGICIIC	CGAAGGAIIIIIAII	00
Query	61	ACCTATATGAACAATTGGCGCAGGAA	CACGACAGCTGAGCAAGAG	GCCCTGCAAGCTAAA	120
Sbjct	61	ACTTATATGGACAATTGGCGCCAGAA	CACAACAGCTGAGCAAGAG	GCCCTCCAAGCCAAA	120
Query	121	GTGGACGCTGAGAATTTCTACTATGT	CATCTTGTACCTTATGGTG	ATGATTGGAATGTTC	180
Sbjct	121	GTTGATGCTGAGAACTTCTACTATGT	CATCCTGTACCTCATGGTG	ATGATTGGAATGTTC	180
Query	181	TCTTTCATCATTGTAGCCATCCTGGT	GAGCACGGTGAAATCCAAG	CGACGAGAACACTCC	240
Sbjct	181	TCTTTCATCATCGTGGCCATCCTGGT	GAGCACTGTGAAATCCAAG	AGACGGGAACACTCC	240
Query	241	AACGACCCCTACCACCAGTACATCGT	AGAGGACTGGCAAGAGAAA 	TACAGGAGTCAAATT 	300
Sbjct	241	AATGACCCCTACCACCAGTACATTGT.	AGAGGACTGGCAGGAAAAG	TACAAGAGCCAAATC	300
Query	301	TTGAATCTAGAGGAACCAAAGGCCAC	CATCCACAAGAACATTAGT	GCAACCGAGTTCCAG	360
Sbjct	301	TTGAATCTAGAAGAATCGAAGGCCAC	CATCCATGAGAACATTGGT	GCGGCTGGGTTCAAA	360
Query	361	ATGTCGCCT <mark>TGA</mark> 372			

Sbjct 361 ATGTCCCCCTGA 372

Protein BLAST

Score		Expect	Method	Identities	Positives	Gaps
234 bits	s(596)) 1e-84	Compositional matrix adjust.	110/123(89%)	117/123(95%	%) 0/123(0%)
Query	1	MPTLSNI M TLSN	TQTLEDVFKKIFITYMNNWRRNTTAEQ TOTLEDVF++IFITYM+NWR+NTTAEO	EALQAKVDAENF <mark>YYVII</mark> EALOAKVDAENFYYVII	<mark>LYLMVMIGMF</mark> (LYLMVMIGMF	50
Sbjct	1	MSTLSNF	, TQTLEDVFRRIFITYMDNW <mark>R</mark> QNTTAEQ	EALQAKVDAENFYYVII	LYLMVMIGMF (50
Query	61	<mark>SFIIVAI</mark> Setivat	LVSTVKSKRREHSNDPYHQYIVEDWQE	KYRSQILNLEEPKATII	IKNISATEFQ 1	120
Sbjct	61	SFIIVAI	LVSTVKSKRREHSNDPYHQYIVEDWQE	KYKSQILNLEESKATIF	HENIG <mark>A</mark> AGFK 1	120
Query	121	MSP 12 MSP	3			
Sbjct	121	MSP 12	3			

Equine 1 XXXLSNLTQTLEDVFKKIFITYMNNWRRNTTAEQEALQAKVDAENFYYVILYLMVMIGMFSFIIVAILVSTVKSKRREHS 80 Human 1 MSTLSNFTQTLEDVFRRIFITYMDNWRQNTTAEQEALQAKVDAENFYYVILYLMVMIGMFSFIIVAILVSTVKSKRREHS 80

Equine	81	NDPYHQYIVEDWQEKYRSQILNLEEPKATIHKNISATEFQMSP	123
Human	81	NDPYHQYIVEDWQEKYKSQILNLEESKATIHENIGAAGFKMSP	123

Figure 12: A protein BLAST without any marking only indicating where there are differences in amino acids.